TK is a cell therapy based on ex vivo genetically modified cells. Its therapeutic approach is based upon the concept that the curative effects of an allogeneic (i.e., from a fully compatible related or unrelated donor) haematopoietic stem cell transplantation strongly relies on the immune advantage conferred by donor T cells, which are able to mediate a potent effect against the disease.

Regrettably, this approach cannot be applied in approximately half of the patients due to the lack of a fully compatible related or unrelated donor.

TK is currently investigated  in a Phase III trial in acute leukaemia patients s in first or subsequent complete remission and at high risk of relapse, suitable for haploidentical (i.e., from a partially compatible related donor) haematopoietic stem cell transplantation. The trial is open for enrolment of up to approximately 170 patients.

MolMed S.p.A. Via Olgettina, 58 - 20132 Milano, Italy | Phone +39 0221277.1 - Fax +39 02 21277.325 | -
Privacy & Cookie Policy | Suppliers' Privacy Policy | Customers' Privacy Policy
Share capital € 21,819,020.83 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159